Developer docs
API playgroundTry for free, no card

Search company profiles

Nabsys

Full company profile

uuid0000of3

Namestring
Nabsys
Legal namestring
Nabsys 2.0 LLC
Websiteurl
nabsys.com
Company typeenum
Private
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersProvidence, United States
HQ citystring
Providence
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electronic genome mapping, structural variant detection, DNA sequencing instruments, genomics analytical software, high molecular weight DNA analysis
Industry2 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Genomics Instrumentation
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1OhmX Platform Hardware
TypeHardware Sales
Description

Sale of the OhmX Analyzer benchtop instrument for genome mapping and structural variant detection.

nabsys.com
2Consumables and Reagents
TypeHardware Sales
Description

Sale of sample preparation kits including the VOLT Whole Genome Kit and other reagents required for the EGM workflow.

nabsys.com
3Software Licenses
TypeSubscription Recurring
Description

Licensing of analytical software including SV-Verify, Human Chromosome Explorer, and RepX Analysis pipelines.

nabsys.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nabsys develops and sells the OhmX Platform, a benchtop Electronic Genome Mapping (EGM) instrument that uses solid-state nanochannel electronic nanodetectors to identify tagged high molecular weight DNA molecules and detect structural variants across the whole genome at 300bp resolution. The product system includes the OhmX Analyzer, nanodetector chips, the VOLT Whole Genome Sample Prep Kit, and secondary analysis software (Human Chromosome Explorer, SV-Verify, and RepX Analysis).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Throughput increased by over 10x following technical milestone achievement
+3 more records
Product overview1 text field

Nabsys offers a unified product portfolio centered on its proprietary Electronic Genome Mapping (EGM) technology implemented on the OhmX Platform. The core offering consists of the OhmX Analyzer hardware with integrated nanodetector chips, supported by the OhmX Sample Prep Kit (VOLT) for DNA preparation. Secondary software products include the Human Chromosome Explorer (HCE) for genome assembly and SV analysis, SV-Verify for hypothesis-based structural variant verification using machine learning, and RepX Analysis for repeat expansion disorder detection. The company operates through a partnership with Hitachi High-Tech and offers the OhmX RAMP UP grant program for research laboratories. The technology focuses on structural variant detection in cancer research, rare disease research, repeat expansion disorders, and cell and gene therapy applications.

Product and service6 records
1OhmX Platform / OhmX Analyzer
CategoryGenomics Instrumentation
Description

Benchtop instrument using proprietary electronic nanodetectors to perform whole-genome structural variant detection down to 300bp, with low cost and minimal setup requirements, targeted at translational genomics researchers and clinical cytogenetics labs.

2OhmX VOLT Whole Genome Sample Prep Kit
CategoryConsumables and Reagents
Description

Consumable kit that uses Velocity Optimized Label and Tagging chemistry to tag high molecular weight DNA at sequence-specific sites, enabling same-day amplification-free sample-to-genome-mapping workflow on the OhmX Platform.

3Nanodetector Chips
CategoryInstrument Components
Description

State-of-the-art electronic nano-detector chips installed in the OhmX Analyzer that deliver whole-genome structural variant analysis down to 300bp using HD-Mapping technology.

4Human Chromosome Explorer (HCE)
CategoryBioinformatics Software
Description

Suite of secondary analytical software tools, co-developed with Hitachi High-Tech, that assembles genomes from OhmX electronic mapping data and identifies structural variants using customer-defined parameters.

5SV-Verify Software
CategoryBioinformatics Software
Description

Machine-learning software package that performs hypothesis-based verification of putative structural variants using support vector machines, testing several thousand independent deletion hypotheses from 300bp to hundreds of kilobases.

6RepX Analysis
CategoryBioinformatics Software
Description

Bioinformatics pipeline that analyzes up to 30 repeat-expansion genes in a single workflow, eliminating the need for multiple locus-specific assays in studies of Fragile X, Friedreich's ataxia, FSHD, and similar disorders.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Collaboration to develop an electronic genome mapping-based assay using the OhmX Platform for facioscapulohumeral muscular dystrophy (FSHD) research, a repeat contraction disease. The partnership aims to address limitations of current diagnostic methods like Southern blot which require radioactivity and significant technical expertise.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-17
Description

RAMP UP (Rapid Application to Market Penetration User Partnership) program collaboration for advancing the OhmX Electronic Genome Mapping Platform. The program includes installations at leading cytogenetic laboratories and sponsored research agreements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-17
Description

Renowned cytogeneticist joined the RAMP UP program to advance electronic genome mapping applications in hematologic malignancies, beginning with acute myeloid leukemia and myelodysplastic syndromes. Multiple OhmX Platforms installed under sponsored research agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Research collaboration to present data at AGBT 2026 on direct genome-scale mapping of endonuclease activity of human LINE-1 ORF2p using EGM on the OhmX Platform. Dr. Taylor's team demonstrated the technology's capability for genome-wide analysis of DNA modifications and damage.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Multi-disciplinary research collaboration using the OhmX Platform for multi-omics studies. Researchers presented data on interstitial cystitis/bladder pain syndrome at ASHG 2025, identifying previously undetected structural variants. Boston Children's Hospital utilized EGM to identify a novel translocation involving NOTCH1.

Strategic tierCoreTypeTechnology or Integration
Description

Joint presentation and demonstration of EGM technology at Japanese Society of Human Genetics 2025 Annual Meeting. Partnership on development and release of Human Chromosome Explorer secondary analytical software tools.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Sample-prep and molecular diagnostics consumables supplier. Comparable as a supplier of nucleic acid preparation and analysis tools used in genomics workflows that include Nabsys-adjacent applications.

TypeBroad incumbent
Description

Analytical instrument and molecular diagnostics company serving genomics and pathology labs. Competes for benchtop instrument budgets in cytogenetics and molecular pathology workflows.

TypeBroad incumbent
Description

Dominant short-read sequencing incumbent whose installed base generates the SV-calls that Nabsys's orthogonal validation product (SV-Verify) is designed to verify. Competes indirectly as the default workflow in many genomics labs.

TypeDirect peer
Description

Long-read sequencing platform (HiFi) increasingly used for structural variant detection and de novo assembly. Competes with Nabsys for SV-detection budgets in genomics labs, though with a different detection modality.

TypeBroad incumbent
Description

Life sciences tools giant with broad genomics, cell therapy, and analytical instrument portfolios. Competes indirectly across multiple Nabsys application areas through instruments and consumables.

TypeDirect peer
Description

Direct competitor offering optical genome mapping for structural variant detection. Most analogous peer as both companies sell benchtop mapping instruments with consumables for SV analysis in cytogenetics and rare disease workflows.

TypeEmerging player
Description

Benchtop sequencing platform targeting multiomic applications including cytogenetics. Overlaps with Nabsys in serving genomics labs with benchtop instruments, though using a different detection chemistry.

TypeBroad incumbent
Description

Genomics tools company offering linked-read sequencing, single-cell, and spatial platforms. Competes for genomics-research capital budgets and offers complementary workflows in cancer and rare disease.

TypeEmerging player
Description

Sequencing platform company offering benchtop sequencers targeting lower-cost, higher-throughput genomics. Competes for genomics lab budgets though not directly in SV detection today.

TypeDirect peer
Description

Long-read sequencing platform used for SV detection, repeat expansion analysis, and rare disease research. Directly competes with OhmX in repeat expansion and structural variant applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nabsys

Genomics Instrumentationnabsys.com

Nabsys firmographics

Firmographics
Name
Nabsys
Legal name
Nabsys 2.0 LLC
Website
https://nabsys.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Nabsys industry classification

Industry
Product category
Genomics Instrumentation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Electronic genome mapping
  • Structural variant detection
  • DNA sequencing instruments
  • Genomics analytical software
  • High molecular weight DNA analysis

Where Nabsys is headquartered

Location

Headquarters

HQ city
Providence
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nabsys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. OhmX Platform Hardware: Sale of the OhmX Analyzer benchtop instrument for genome mapping and structural variant detection.
  2. Consumables and Reagents: Sale of sample preparation kits including the VOLT Whole Genome Kit and other reagents required for the EGM workflow.
  3. Software Licenses: Licensing of analytical software including SV-Verify, Human Chromosome Explorer, and RepX Analysis pipelines.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Nabsys product offering

Product offering

Core offering

Nabsys develops and sells the OhmX Platform, a benchtop Electronic Genome Mapping (EGM) instrument that uses solid-state nanochannel electronic nanodetectors to identify tagged high molecular weight DNA molecules and detect structural variants across the whole genome at 300bp resolution. The product system includes the OhmX Analyzer, nanodetector chips, the VOLT Whole Genome Sample Prep Kit, and secondary analysis software (Human Chromosome Explorer, SV-Verify, and RepX Analysis).

Product overview

Nabsys offers a unified product portfolio centered on its proprietary Electronic Genome Mapping (EGM) technology implemented on the OhmX Platform. The core offering consists of the OhmX Analyzer hardware with integrated nanodetector chips, supported by the OhmX Sample Prep Kit (VOLT) for DNA preparation. Secondary software products include the Human Chromosome Explorer (HCE) for genome assembly and SV analysis, SV-Verify for hypothesis-based structural variant verification using machine learning, and RepX Analysis for repeat expansion disorder detection. The company operates through a partnership with Hitachi High-Tech and offers the OhmX RAMP UP grant program for research laboratories. The technology focuses on structural variant detection in cancer research, rare disease research, repeat expansion disorders, and cell and gene therapy applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • OhmX Platform / OhmX Analyzer Benchtop instrument using proprietary electronic nanodetectors to perform whole-genome structural variant detection down to 300bp, with low cost and minimal setup requirements, targeted at translational genomics researchers and clinical cytogenetics labs.
  • OhmX VOLT Whole Genome Sample Prep Kit Consumable kit that uses Velocity Optimized Label and Tagging chemistry to tag high molecular weight DNA at sequence-specific sites, enabling same-day amplification-free sample-to-genome-mapping workflow on the OhmX Platform.
  • Nanodetector Chips State-of-the-art electronic nano-detector chips installed in the OhmX Analyzer that deliver whole-genome structural variant analysis down to 300bp using HD-Mapping technology.
  • Human Chromosome Explorer (HCE) Suite of secondary analytical software tools, co-developed with Hitachi High-Tech, that assembles genomes from OhmX electronic mapping data and identifies structural variants using customer-defined parameters.
  • SV-Verify Software Machine-learning software package that performs hypothesis-based verification of putative structural variants using support vector machines, testing several thousand independent deletion hypotheses from 300bp to hundreds of kilobases.
  • RepX Analysis Bioinformatics pipeline that analyzes up to 30 repeat-expansion genes in a single workflow, eliminating the need for multiple locus-specific assays in studies of Fragile X, Friedreich's ataxia, FSHD, and similar disorders.

Quantifiable outcome

  • Throughput increased by over 10x following technical milestone achievement
  • +3 more outcomes

Companies that use Nabsys

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Nabsys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Nabsys partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Leiden University Medical Center (LUMC)coreStrategic or Co-development Partner · 15 June 2026Collaboration to develop an electronic genome mapping-based assay using the OhmX Platform for facioscapulohumeral muscular dystrophy (FSHD) research, a repeat contraction disease. The partnership aims to address limitations of current diagnostic methods like Southern blot which require radioactivity and significant technical expertise.
  • Hitachi High-Tech America (RAMP UP Program)coreGTM or Marketing Partner · 17 May 2026RAMP UP (Rapid Application to Market Penetration User Partnership) program collaboration for advancing the OhmX Electronic Genome Mapping Platform. The program includes installations at leading cytogenetic laboratories and sponsored research agreements.
  • Columbia University (Dr. Brynn Levy)coreStrategic or Co-development Partner · 17 May 2026Renowned cytogeneticist joined the RAMP UP program to advance electronic genome mapping applications in hematologic malignancies, beginning with acute myeloid leukemia and myelodysplastic syndromes. Multiple OhmX Platforms installed under sponsored research agreement.
  • Brown University (Dr. Martin Taylor Lab)coreStrategic or Co-development Partner · 24 February 2026Research collaboration to present data at AGBT 2026 on direct genome-scale mapping of endonuclease activity of human LINE-1 ORF2p using EGM on the OhmX Platform. Dr. Taylor's team demonstrated the technology's capability for genome-wide analysis of DNA modifications and damage.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 16 October 2025Multi-disciplinary research collaboration using the OhmX Platform for multi-omics studies. Researchers presented data on interstitial cystitis/bladder pain syndrome at ASHG 2025, identifying previously undetected structural variants. Boston Children's Hospital utilized EGM to identify a novel translocation involving NOTCH1.
  • Hitachi High-Tech CorporationcoreTechnology or IntegrationJoint presentation and demonstration of EGM technology at Japanese Society of Human Genetics 2025 Annual Meeting. Partnership on development and release of Human Chromosome Explorer secondary analytical software tools.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Nabsys competitors and assessment

Company assessment

Others

  • QIAGEN: Sample-prep and molecular diagnostics consumables supplier. Comparable as a supplier of nucleic acid preparation and analysis tools used in genomics workflows that include Nabsys-adjacent applications.

Broad incumbents

  • Agilent Technologies: Analytical instrument and molecular diagnostics company serving genomics and pathology labs. Competes for benchtop instrument budgets in cytogenetics and molecular pathology workflows.
  • Illumina: Dominant short-read sequencing incumbent whose installed base generates the SV-calls that Nabsys's orthogonal validation product (SV-Verify) is designed to verify. Competes indirectly as the default workflow in many genomics labs.
  • Thermo Fisher Scientific: Life sciences tools giant with broad genomics, cell therapy, and analytical instrument portfolios. Competes indirectly across multiple Nabsys application areas through instruments and consumables.
  • 10x Genomics: Genomics tools company offering linked-read sequencing, single-cell, and spatial platforms. Competes for genomics-research capital budgets and offers complementary workflows in cancer and rare disease.

Direct peers

  • Pacific Biosciences: Long-read sequencing platform (HiFi) increasingly used for structural variant detection and de novo assembly. Competes with Nabsys for SV-detection budgets in genomics labs, though with a different detection modality.
  • Bionano Genomics: Direct competitor offering optical genome mapping for structural variant detection. Most analogous peer as both companies sell benchtop mapping instruments with consumables for SV analysis in cytogenetics and rare disease workflows.
  • Oxford Nanopore Technologies: Long-read sequencing platform used for SV detection, repeat expansion analysis, and rare disease research. Directly competes with OhmX in repeat expansion and structural variant applications.

Emerging players

  • Singular Genomics: Benchtop sequencing platform targeting multiomic applications including cytogenetics. Overlaps with Nabsys in serving genomics labs with benchtop instruments, though using a different detection chemistry.
  • Element Biosciences: Sequencing platform company offering benchtop sequencers targeting lower-cost, higher-throughput genomics. Competes for genomics lab budgets though not directly in SV detection today.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nabsys social profiles

Digital presence

Nabsys compliance and trust

Trust signal

Compliance1 record

Nabsys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nabsys leadership team

Management profile

Number of profiles

Profiles8 records

Nabsys funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nabsys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nabsys

What does Nabsys do?

Nabsys develops and sells the OhmX Platform, a benchtop Electronic Genome Mapping (EGM) instrument that uses solid-state nanochannel electronic nanodetectors to identify tagged high molecular weight DNA molecules and detect structural variants across the whole genome at 300bp resolution. The product system includes the OhmX Analyzer, nanodetector chips, the VOLT Whole Genome Sample Prep Kit, and secondary analysis software (Human Chromosome Explorer, SV-Verify, and RepX Analysis).

Is Nabsys a public or private company?

Nabsys is a private company. It is classified as corporate owned and is currently operating.

When was Nabsys founded?

Nabsys was founded in 2005. It employs 51 to 100 people.

Where is Nabsys based?

Nabsys is headquartered in Providence, United States, in the North America region.

How does Nabsys make money?

Three revenue lines are on record. OhmX Platform Hardware is the primary driver. The others are consumables and Reagents and software Licenses.

Who are Nabsys's main competitors?

QIAGEN is listed as an others. Broad incumbents are Agilent Technologies, Illumina, Thermo Fisher Scientific and 10x Genomics. Direct peers are Pacific Biosciences, Bionano Genomics and Oxford Nanopore Technologies. Emerging players are Singular Genomics and Element Biosciences.

Does Nabsys have an API?

No public API is recorded for Nabsys.

What industry is Nabsys in?

Nabsys's product category is Genomics Instrumentation. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEENabsys to Highlight Electronic Genome Mapping Findings from Leading Hematopathology Experts at AMP 2026 ...Middle EastNabsys announced that researchers from Augusta University and MD Anderson Cancer Center will present findings on structural variant detection in hematologic malignancies using electronic genome mapping at AMP 2026 in Providence, R.I., on Nov. 5, 2026. The announcement was made via PR Newswire.PR NewswireNabsys to Highlight Electronic Genome Mapping Findings from Leading Hematopathology Experts at AMP 2026Researchers from Augusta University and UT MD Anderson will present Electronic Genome Mapping findings for structural variant detection in hematologic malignancies at AMP 2026 in Seattle. The EGM approach detects abnormalities from peripheral blood without culture, and Nabsys will showcase its OhmX platform at booth 937.GenengnewsASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic CancersNabsys presented preliminary data on its Electronic Genome Mapping (EGM) technology for hematologic malignancies at ASHG 2026, showing how it detects structural and copy number variants. The company also previewed its Nabsys Navigator analysis software, which includes pipelines for structural variant discovery and verification. The OhmX Platform is for research use only.PR NewswireNabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 2026Nabsys announced RepX, a repeat expansion analysis pipeline for its OhmX platform, available through Nabsys Navigator. The pipeline can analyze up to 23 disease-associated loci in a single low-cost run. Nabsys will demonstrate RepX at ASHG 2026 in Montréal.BioSpaceNabsys Announces First Publication Showcasing CRISPR/Cas9 Mediated Approach to Expand the Capabilities of Electronic Genome MappingNabsys announced a preprint demonstrating CRISPR/Cas9 combined with Electronic Genome Mapping (EGM) to characterize CRISPR activity and expand genome mapping. The study shows EGM can detect FXN repeat expansions in Friedreich Ataxia and is available on bioRxiv.BioSpaceNabsys Announces the First Publication from Augusta University Demonstrating the Potential of Electronic Genome Mapping for High-Resolution Analysis of Hematologic MalignanciesNabsys announced a proof-of-principle study from Augusta University showing its Electronic Genome Mapping (EGM) platform detected all pathogenic abnormalities in five hematologic malignancy samples, matching standard cytogenetic and optical genome mapping. The study also identified additional structural variants, including a 1.8 Mb loss at 7q22.1, and supports further evaluation in larger cohorts.AijournNabsys and Indiana University Collaborate to Advance Electronic Genome Mapping Applications in Hematologic MalignanciesNabsys 2.0, LLC announced a multi-year research collaboration with the Indiana University School of Medicine to develop and evaluate Electronic Genome Mapping applications for hematologic malignancies, initially focusing on acute myeloid leukemia and myelodysplastic syndromes. Dr. Kevin T.A. Booth from Indiana University will evaluate Nabsys' OhmX Platform, which uses proprietary electronic detection to analyze ultra-long DNA molecules for structural variant and copy number analysis. Nabsys will present its EGM research at the Cancer Genomics Consortium Annual Meeting in August 2026 in Houston, Texas.PR NewswireNabsys and Indiana University Collaborate to Advance Electronic Genome Mapping Applications in Hematologic MalignanciesNabsys 2.0, LLC announced a multi-year research collaboration with the Indiana University School of Medicine to develop and evaluate Electronic Genome Mapping applications for hematologic malignancies, initially focused on acute myeloid leukemia and myelodysplastic syndromes. The collaboration will utilize Nabsys' OhmX Platform, which uses proprietary electronic detection to analyze ultra-long DNA molecules for structural variant and copy number analysis, with Dr. Kevin T.A. Booth leading the evaluation at Indiana University. The partnership may extend to additional hematologic malignancies and constitutional disorders over time.BostonGlobe.comNabsys to move to new headquarters, add more than 200 jobs in ProvidenceNabsys, a Providence-based life sciences company specializing in electronic genome mapping, is planning to relocate its headquarters from 60 Clifford St. to the top floor of 225 Dyer St. in the city's 195 District in summer 2027. The company will occupy 300,000 square feet of office space and expects to add more than 200 jobs as part of the expansion.Providence Business NewsNabsys to begin build-out of new I-195 District headquartersState officials and Nabsys 2.0 executives held a press conference on the seventh floor of the Wexford Science & Technology building in the I-195 Redevelopment District. The company will build out and occupy its 30,000-square-foot headquarters there.